Editas Medicine (EDIT) Names New Chief Scientific Officer
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
Editas Medicine, Inc. (NASDAQ: EDIT), a leading genome editing company, announced today the appointment of Charles Albright, Ph.D. as Chief Scientific Officer. Dr. Albright brings to Editas more than 25 years of life sciences industry and academic leadership experience, most recently serving as Vice President of Genetically Defined Diseases and Genomics at Bristol-Myers Squibb (BMS).
“Charlie has an impressive track record of translating exciting science into real medicines for patients in need,” said Katrine Bosley, President and Chief Executive Officer of Editas Medicine. “He has brought numerous new medicines from discovery into clinical development across many disease areas. During this period of significant growth at Editas, I am very pleased to welcome him to the team and look forward to his many contributions as we continue to build this organization for the long-term.”
“As a leader in the field, Editas is building an impressive and diversified pipeline focused on treating patients with a broad range of genetically defined diseases,” said Dr. Albright. “I am excited to join the dynamic team at Editas and to help pioneer this exciting wave of innovation around genomic medicines.”
Over his career, Dr. Albright has led discovery programs that advanced investigational medicines into clinical development in a wide range of therapeutic areas, including neurodegeneration, pain, psychiatry, oncology and inflammation. Prior to his position as Vice President of Genetically Defined Diseases and Genomics, he held multiple scientific leadership roles in Neuroscience Biology at BMS. Previously, he held positions at Incyte Corporation and DuPont Pharmaceuticals and was an Assistant Professor of Biochemistry at Vanderbilt University. Dr. Albright received a Bachelor of Science in Chemical Engineering and a Ph.D. in Biology from the Massachusetts Institute of Technology (MIT). He was a postdoctoral fellow in the laboratory of Professor Robert Weinberg at the Whitehead Institute for Biomedical Research at MIT.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Analogic (ALOG) CEO Green Resigns; Successor Named
- Advaxis (ADXS) Announces Topline Data from Phase 2 GOG-0265 Stage 2; OS Data Consistent with Prior Results
- Crow Holdings Taps Morgan Stanley's (MS) Michael Levy for Senior Leadership Role
Create E-mail Alert Related CategoriesCorporate News, Management Changes, Management Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!